History

Semax was developed in Russia at the Institute of Molecular Genetics of the Russian Academy of Sciences and first described around 1991. It is built from the ACTH(4-10) fragment, which carries the hormone's attention- and memory-related activity without triggering cortisol release; adding a C-terminal Pro-Gly-Pro sequence greatly extends its stability. It has been used in Russian clinical practice since the 1990s for ischemic stroke, transient ischemic attack, and cognitive disorders, and was added to Russia's List of Vital & Essential Drugs on December 7, 2011.

Semax is a synthetic peptide developed in Russia in the late 1980s and used there as a prescription drug for stroke and cognitive disorders. It is not approved anywhere in the West, and most of the research is in Russian.

What it is

Semax is a heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is a synthetic analog of a fragment of adrenocorticotropic hormone (ACTH 4-10), modified with a proline-glycine-proline tail to slow breakdown. It was first described in the scientific literature around 1991 and is usually given intranasally. In Russia it is a registered medicine and appears on the country’s List of Vital and Essential Drugs, prescribed for ischemic stroke, cerebrovascular disorders, cognitive impairment, and some optic nerve conditions.

The claims

Semax is marketed online as a “nootropic” said to sharpen focus, memory, and motivation; protect or repair neurons after a stroke; and ease anxiety and low mood. The most common mechanistic claim is that it rapidly raises brain-derived neurotrophic factor (BDNF), a protein involved in neuroplasticity.

What the evidence actually shows

The mechanism is plausible but not fully pinned down. Animal studies do show Semax can raise BDNF and its TrkB receptor and influence dopamine and serotonin signaling; it may also interact with melanocortin receptors or slow peptide-degrading enzymes. The exact pathway in humans remains unclear.

Human data exist but are limited. The clearest trials are small Russian stroke studies. One controlled trial in the acute period of hemispheric ischemic stroke gave Semax to 30 patients versus 80 on conventional therapy and reported some influence on the pace of neurological recovery, without clearly described randomization or blinding. Other small studies report better motor scores, raised plasma BDNF, and improved daily-function (Barthel) scores. Cognitive and mood claims rest on small volunteer studies (for example, EEG changes and better memory-test scores) and on decades of Russian clinical use rather than large, blinded, peer-reviewed trials. There are no published Western randomized controlled trials, no long-term safety studies, and much of the literature is untranslated. The result is suggestive, not conclusive.

Legal and regulatory status

Semax is not approved by the FDA, the EMA, or other Western regulators for any use. In the United States its status under the drug-compounding rules has been in flux. In 2023 the FDA placed Semax in “Category 2” — bulk substances it considered to raise significant safety concerns for compounding under section 503A. In April 2026 the agency announced that Semax (along with several other peptides) was being removed from Category 2 because the underlying nominations had been withdrawn. Importantly, removal from Category 2 does not by itself authorize compounding: Semax has not been added to the 503A bulks list, and the FDA has not said it will exercise enforcement discretion. The FDA’s Pharmacy Compounding Advisory Committee is scheduled to discuss whether Semax (free base and acetate) should be added to the 503A bulks list at a public meeting held July 23-24, 2026 (Semax is on the July 24 agenda; Docket FDA-2026-N-2979). As of this writing no decision has been made. Semax is also widely sold online as a “research chemical,” which is not a lawful route for human use.

For athletes: Semax is not named individually on the WADA Prohibited List, but as a substance with no approval from any government health authority for human use, it falls under category S0 (Non-Approved Substances), which is prohibited at all times. Under strict liability, an athlete is responsible for anything found in their system.

Safety

Russian clinical use over several decades and small studies suggest Semax is generally well tolerated short-term, with few reported side effects. But there is no rigorous long-term safety data, no Western regulatory review, and real uncertainty about the purity of material sold online. Treat the safety picture as incomplete.

Bottom line

Semax has a longer real-world track record than most “research” peptides and some genuine human data behind it, but the trials are small, mostly Russian-language, and methodologically weak by modern standards. The benefits for cognition and stroke recovery are plausible and partly supported, not proven. This is not medical advice.

Evidence grade: Preliminary human.